Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| AM-Pharma | Ambrose Healthcare | Proprietary & Advanced Pharmaceuticals | $161M | n/m | |
| Chr. Olesen Synthesis A/S | Samfara LLP | Proprietary & Advanced Pharmaceuticals | $115M – $155M | 10× – 14× | |
| Recordati | Respighi BidCo, CVC, GBL | Proprietary & Advanced Pharmaceuticals | $72.8M | 12× – 16× | |
| Intra-Cellular Therapies | Johnson & Johnson | Proprietary & Advanced Pharmaceuticals | $23,300M | 12× – 15× | |
| Pacira BioSciences | Viatris | Proprietary & Advanced Pharmaceuticals | $1,650M | 7× – 10× | |
| IntraBio | Shionogi | Proprietary & Advanced Pharmaceuticals | $2,000M | n/m | |
| Recordati | CVC Capital Partners, Groupe Bruxelles Lambert (GBL) | Proprietary & Advanced Pharmaceuticals | $11,800M | 16× – 21× | |
| Pacira BioSciences, Inc. | Viatris Inc. | Proprietary & Advanced Pharmaceuticals | $1,650M | 8× – 11× | |
| Mentara Therapeutics | SPRIM Global Investments | Proprietary & Advanced Pharmaceuticals | $17.0M – $23.0M | n/m | |
| 艾力斯医药科技股份有限公司 (Alis Pharmaceutical Technology Co., Ltd.) | ArriVent BioPharma | Proprietary & Advanced Pharmaceuticals | $0.0M | 0× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.